5-Nitro-3-(2-(4-phenylthiazol-2-yl)hydrazineylidene)indolin-2-one derivatives inhibit HIV-1 replication by a multitarget mechanism of action

In the effort to identify and develop new HIV-1 inhibitors endowed with innovative mechanisms, we focused our attention on the possibility to target more than one viral encoded enzymatic function with a single molecule. In this respect, we have previously identified by virtual screening a new indolinone-based scaffold for dual allosteric inhibitors targeting both reverse transcriptase-associated functions: polymerase and RNase H. Pursuing with the structural optimization of these dual inhibitors, we synthesized a series of 35 new 3-[2-(4-aryl-1,3-thiazol-2-ylidene)hydrazin-1-ylidene]1-indol-2-one and 3-[3-methyl-4-arylthiazol-2-ylidene)hydrazine-1-ylidene)indolin-2-one derivatives, which maintain their dual inhibitory activity in the low micromolar range. Interestingly, compounds 1a, 3a, 10a, and 9b are able to block HIV-1 replication with EC50 < 20 µM. Mechanism of action studies showed that such compounds could block HIV-1 integrase. In particular, compound 10a is the most promising for further multitarget compound development.

[1]  A. Das,et al.  HIV-1 3′-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles , 2023, Journal of virology.

[2]  Qin Ouyang,et al.  Recent advances on dual inhibitors targeting HIV reverse transcriptase associated polymerase and ribonuclease H. , 2023, European journal of medicinal chemistry.

[3]  P. Zhan,et al.  Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors. , 2022, European journal of medicinal chemistry.

[4]  V. Calvez,et al.  Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration , 2022, Journal of virology.

[5]  Dongwei Kang,et al.  Novel RNase H inhibitors blocking RNA-directed strand displacement DNA synthesis by HIV-1 reverse transcriptase. , 2022, Journal of molecular biology.

[6]  W. L. Jorgensen,et al.  Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase , 2022, Frontiers in Molecular Biosciences.

[7]  A. Das,et al.  Mutations in the HIV-1 3′-Polypurine Tract Can Confer Dolutegravir Resistance , 2021, Antimicrobial agents and chemotherapy.

[8]  P. Mátyus,et al.  Exploring New Scaffolds for the Dual Inhibition of HIV-1 RT Polymerase and Ribonuclease Associated Functions , 2021, Molecules.

[9]  P. Caboni,et al.  Flavonoids and Acid-Hydrolysis derivatives of Neo-Clerodane diterpenes from Teucrium flavum subsp. glaucum as inhibitors of the HIV-1 reverse transcriptase–associated RNase H function , 2021, Journal of enzyme inhibition and medicinal chemistry.

[10]  E. Ballana,et al.  Targeting HIV-1 RNase H: N’-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants , 2020, Viruses.

[11]  A. Engelman,et al.  Close‐up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms , 2020, The FEBS journal.

[12]  E. Novellino,et al.  Discovery of dihydroxyindole-2-carboxylic acid derivatives as dual allosteric HIV-1 Integrase and Reverse Transcriptase associated Ribonuclease H inhibitors. , 2019, Antiviral research.

[13]  E. Tramontano,et al.  Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity. , 2019, European journal of medicinal chemistry.

[14]  R. Shafer,et al.  2019 update of the drug resistance mutations in HIV-1. , 2019, Topics in antiviral medicine.

[15]  S. Ekins,et al.  New targets for HIV drug discovery. , 2019, Drug discovery today.

[16]  P. Boyer,et al.  Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase , 2018, Journal of Virology.

[17]  Rona R. Ramsay,et al.  A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.

[18]  Tulio de Oliveira,et al.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis , 2017, The Lancet. Infectious diseases.

[19]  C. Floris,et al.  Natural product-inspired esters and amides of ferulic and caffeic acid as dual inhibitors of HIV-1 reverse transcriptase. , 2017, European journal of medicinal chemistry.

[20]  C. Tintori,et al.  Natural Product Kuwanon‐L Inhibits HIV‐1 Replication through Multiple Target Binding , 2017, Chembiochem : a European journal of chemical biology.

[21]  R. Ghirlando,et al.  Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome , 2017, Science.

[22]  Jiawen Li,et al.  HIV-1 Reverse Transcriptase Polymerase and RNase H (Ribonuclease H) Active Sites Work Simultaneously and Independently* , 2016, The Journal of Biological Chemistry.

[23]  E. Tramontano,et al.  Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase , 2016, Journal of enzyme inhibition and medicinal chemistry.

[24]  E. Novellino,et al.  New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H. , 2016, Antiviral research.

[25]  S. L. Le Grice,et al.  Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6 , 2016, PloS one.

[26]  C. Tintori,et al.  Kuwanon‐L as a New Allosteric HIV‐1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation , 2015, Chembiochem : a European journal of chemical biology.

[27]  V. Calvez,et al.  Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. , 2015, The Journal of antimicrobial chemotherapy.

[28]  P. Mátyus,et al.  (3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase. , 2015, European journal of medicinal chemistry.

[29]  D. N. Levy,et al.  Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration , 2015, Retrovirology.

[30]  E. Novellino,et al.  Identification of Highly Conserved Residues Involved in Inhibition of HIV-1 RNase H Function by Diketo Acid Derivatives , 2014, Antimicrobial Agents and Chemotherapy.

[31]  M. Fresta,et al.  Design, Synthesis, and Biological Evaluation of 1,3‐Diarylpropenones as Dual Inhibitors of HIV‐1 Reverse Transcriptase , 2014, ChemMedChem.

[32]  E. Tramontano,et al.  Past and Future. Current Drugs Targeting HIV-1 Integrase and Reverse Transcriptase-Associated Ribonuclease H Activity: Single and Dual Active Site Inhibitors , 2014, Antiviral chemistry & chemotherapy.

[33]  E. Tramontano,et al.  Can the ever-promising target HIV reverse transcriptase-associated RNase H become a success story for drug development? , 2014 .

[34]  A. Marchand,et al.  LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014) , 2014, Expert opinion on therapeutic patents.

[35]  O. Delelis,et al.  Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle , 2013, Retrovirology.

[36]  E. Tramontano,et al.  Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors. , 2013, Current pharmaceutical design.

[37]  Stefano Alcaro,et al.  Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. , 2012, European journal of medicinal chemistry.

[38]  A. Engelman,et al.  Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2012, The Journal of Biological Chemistry.

[39]  H. Walter,et al.  Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation , 2012, Intervirology.

[40]  S. Hughes,et al.  The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC. , 2011, Virology.

[41]  A. D. Clark,et al.  Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. , 2011, Journal of medicinal chemistry.

[42]  Martin Sippel,et al.  Molecular Dynamics Simulations of the HIV-1 Integrase Dimerization Interface: Guidelines for the Design of a Novel Class of Integrase Inhibitors , 2010, J. Chem. Inf. Model..

[43]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. , 2009, Structure.

[44]  M. Kvaratskhelia,et al.  An Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule , 2009, Molecular Pharmacology.

[45]  Kerim Babaoglu,et al.  Affinities between the Binding Partners of the HIV-1 Integrase Dimer-Lens Epithelium-derived Growth Factor (IN Dimer-LEDGF) Complex , 2009, The Journal of Biological Chemistry.

[46]  S. Sarafianos,et al.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. , 2009, Journal of molecular biology.

[47]  Hualiang Jiang,et al.  Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase , 2008, Acta Pharmacologica Sinica.

[48]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[49]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[50]  A. Engelman,et al.  Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  T. Steitz,et al.  Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Robert Craigie,et al.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). 1983. , 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[54]  J. DeStefano,et al.  Mutations in the ribonuclease H active site of HIV-RT reveal a role for this site in stabilizing enzyme-primer-template binding. , 2002, Biochemistry.

[55]  S. Sarafianos,et al.  Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D I Stuart,et al.  Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.

[57]  Yvonne Jones,et al.  High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.

[58]  T. Steitz,et al.  Recombining the structures of HIV integrase, RuvC and RNase H. , 1995, Structure.

[59]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[60]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[61]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[62]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[63]  R. Craigie,et al.  HIV integrase structure and function. , 1999, Advances in virus research.

[64]  Thomas A. Halgren,et al.  Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular. interactions , 1996, J. Comput. Chem..